Journal
THROMBOSIS AND HAEMOSTASIS
Volume 110, Issue 5, Pages 868-875Publisher
GEORG THIEME VERLAG KG
DOI: 10.1160/TH13-02-0084
Keywords
-
Categories
Ask authors/readers for more resources
The clinical value of antiplatelet compounds strongly depends on the 1 benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
